• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Bangladesh·Healthcare·BXP.L
Share

Beximco Pharmaceuticals PLC. Stocks

£ 52Last Updated 28.07.2026

Issuer Rating

4/7
Performance

Strong

Risk

High

Recommendation

Hold

Market Cap

£ 309.00M

£ 52
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1976 and headquartered in Dhaka, Bangladesh, Beximco Pharmaceuticals Limited is a prominent company engaged in the production and distribution of generic pharmaceutical formulations and active pharmaceutical ingredients (APIs). The firm’s extensive product line addresses a wide range of therapeutic areas, including treatments for allergic disorders, pain and fever, various infections (antibacterial and antiviral), cardiovascular conditions, central nervous system ailments, respiratory illnesses, endocrine disorders, diabetes, gastrointestinal problems, hormonal therapies, oncology, musculoskeletal issues, and skin conditions. Its offerings also encompass eye care products, vitamin and mineral supplements, and intravenous fluids. These medications are supplied in a comprehensive array of dosage forms, such as solids, liquids, creams, ointments, suppositories, metered-dose and dry powder inhalers, nasal sprays, sterile injectables (including lyophilized forms), and large volume intravenous fluids. Beyond its own diverse portfolio, Beximco Pharmaceuticals provides contract manufacturing services to other companies and actively exports its products internationally.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, underpriced

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

30.07.2026 12:36

A tanker carrying cargo for a Chevron subsidiary was attacked by drones in the Black Sea

30.07.2026 11:58

Samsung's chip business profits have surged 255-fold. Why are its shares soaring?

30.07.2026 10:50

Top Stories This Morning: U.S. Strikes Iran, AI Helps Samsung, EU to Tighten Oversight of ChatGPT

30.07.2026 09:00

Airbus's profits exceeded expectations amid an increase in aircraft deliveries

30.07.2026 08:00

Citi recommended buying Ford shares following the earnings report. Why does the bank expect them to rise by 33%?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026